Curative endoscopic submucosal dissection for esophageal squamous cell carcinoma after chemoradiotherapy for pharyngeal cancer: A case report.

IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Shion Tachibana, Kentaro Moriichi, Keitaro Takahashi, Masahiro Sato, Yu Kobayashi, Yuya Sugiyama, Takahiro Sasaki, Aki Sakatani, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Hiroki Tanabe, Mikihiro Fujiya
{"title":"Curative endoscopic submucosal dissection for esophageal squamous cell carcinoma after chemoradiotherapy for pharyngeal cancer: A case report.","authors":"Shion Tachibana, Kentaro Moriichi, Keitaro Takahashi, Masahiro Sato, Yu Kobayashi, Yuya Sugiyama, Takahiro Sasaki, Aki Sakatani, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Hiroki Tanabe, Mikihiro Fujiya","doi":"10.4251/wjgo.v17.i4.101123","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is often managed with surgery, which is the first-line treatment option for stage I-III lesions. However, definitive chemoradiotherapy (dCRT) is associated with a recurrence rate of 30% in stage I ESCC and higher rates in advanced-staged lesions. However, several patients prefer dCRT because their general condition is poor. Salvage therapies, including esophagectomy and endoscopic resection [endoscopic submucosal dissection (ESD)/endoscopic mucosal resection], are important for residual or recurrent tumors that develop after dCRT. Esophagectomy can have curative potential. However, it has high complication and mortality rates. Therefore, ESD is a safer alternative.</p><p><strong>Case summary: </strong>A Japanese man in his 70s was concurrently diagnosed with right hypopharyngeal cancer (T2N1M0, cStage III), left oropharyngeal cancer (T1N0M0, cStage I), and left hard palate cancer (T1N0M0, cStage I). Esophagogastroduodenoscopy (EGD) revealed a 20 mm reddish 0-Is+IIb lesion in the upper thoracic esophagus, with an invasion depth of SM2. The lesion was diagnosed as an esophageal moderately differentiated squamous cell carcinoma (T1bN0M0, cStage I). As the pharyngeal cancers were in advanced stages, chemoradiotherapy (docetaxel and cisplatin with a radiation dose of 66 Gy) was prioritized. Post-chemoradiotherapy EGD showed that the lesion had flattened into a 0-IIb lesion, thereby indicating a reduced invasion depth (epithelium or lamina propria mucosa). ESD achieved <i>en bloc</i> and histologically confirmed curative resection. At 22 months after ESD, the patient did not present with signs of recurrence.</p><p><strong>Conclusion: </strong>This case emphasizes that ESD can be successfully utilized as a salvage treatment for ESCC after chemoradiotherapy for otolaryngological cancers.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 4","pages":"101123"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995334/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v17.i4.101123","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is often managed with surgery, which is the first-line treatment option for stage I-III lesions. However, definitive chemoradiotherapy (dCRT) is associated with a recurrence rate of 30% in stage I ESCC and higher rates in advanced-staged lesions. However, several patients prefer dCRT because their general condition is poor. Salvage therapies, including esophagectomy and endoscopic resection [endoscopic submucosal dissection (ESD)/endoscopic mucosal resection], are important for residual or recurrent tumors that develop after dCRT. Esophagectomy can have curative potential. However, it has high complication and mortality rates. Therefore, ESD is a safer alternative.

Case summary: A Japanese man in his 70s was concurrently diagnosed with right hypopharyngeal cancer (T2N1M0, cStage III), left oropharyngeal cancer (T1N0M0, cStage I), and left hard palate cancer (T1N0M0, cStage I). Esophagogastroduodenoscopy (EGD) revealed a 20 mm reddish 0-Is+IIb lesion in the upper thoracic esophagus, with an invasion depth of SM2. The lesion was diagnosed as an esophageal moderately differentiated squamous cell carcinoma (T1bN0M0, cStage I). As the pharyngeal cancers were in advanced stages, chemoradiotherapy (docetaxel and cisplatin with a radiation dose of 66 Gy) was prioritized. Post-chemoradiotherapy EGD showed that the lesion had flattened into a 0-IIb lesion, thereby indicating a reduced invasion depth (epithelium or lamina propria mucosa). ESD achieved en bloc and histologically confirmed curative resection. At 22 months after ESD, the patient did not present with signs of recurrence.

Conclusion: This case emphasizes that ESD can be successfully utilized as a salvage treatment for ESCC after chemoradiotherapy for otolaryngological cancers.

咽喉癌放化疗后食管鳞状细胞癌的内镜下粘膜下剥离治疗1例。
背景:食管鳞状细胞癌(ESCC)通常采用手术治疗,这是I-III期病变的一线治疗选择。然而,明确的放化疗(dCRT)与一期ESCC的复发率为30%相关,在晚期病变中复发率更高。然而,也有一些患者因为一般情况较差而选择dCRT。挽救性治疗,包括食管切除术和内镜下切除[内镜粘膜下剥离(ESD)/内镜下粘膜切除术],对于dCRT后发生的残留或复发肿瘤很重要。食管切除术有治愈的潜力。然而,它有很高的并发症和死亡率。因此,ESD是一种更安全的选择。病例总结:一名70多岁的日本男性同时被诊断为右侧下咽癌(T2N1M0, cStage III)、左侧口咽癌(T1N0M0, cStage I)和左侧硬腭癌(T1N0M0, cStage I)。食管胃十二指肠镜(EGD)示上胸食管20 mm红色0-Is+IIb病灶,浸润深度SM2。病变诊断为食管中分化鳞状细胞癌(T1bN0M0, cStage I)。由于咽癌处于晚期,优先考虑放化疗(多西紫杉醇+顺铂,放疗剂量66 Gy)。放化疗后EGD显示病变变平为0-IIb级病变,表明侵袭深度(上皮或固有层粘膜)减小。ESD实现了整体和组织学证实的治愈性切除。在ESD术后22个月,患者未出现复发迹象。结论:本病例强调了ESD可以成功地作为耳鼻咽喉癌放化疗后ESCC的补救性治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology Medicine-Gastroenterology
CiteScore
4.20
自引率
3.30%
发文量
1082
期刊介绍: The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信